ACR Meeting Abstracts

ACR Meeting Abstracts

Session » Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Safety I

Meeting: 2012 ACR/ARHP Annual Meeting

Abstract Number: 1640
Long-Term Safety of Tocilizumab in Patients with Rheumatoid Arthritis and a Mean Treatment Duration of 3.7 Years
Abstract Number: 1641
When Can Biological Therapy Be Resumed in Patients with Rheumatic Conditions Who Develop Tuberculosis Infection During Tumour Necrosis Factors Antagonists Therapy? Study Based On the Biobadaser Data Registry
Abstract Number: 1642
Biologics and Mortality Risk in Rheumatoid Arthritis – Results of a Population Based Study
Abstract Number: 1643
Outcomes of Pregnancy in Subjects Exposed to Certolizumab Pegol
Abstract Number: 1644
Enhanced Pharmacovigilance Reporting of Malignancies in Children and Young Adults Taking Etanercept
Abstract Number: 1645
Combination of Isoniazid for Latent Tuberculosis with Traditional and/or Biologic Disease Modifying Anti-Rheumatic Drugs Is Well Tolerated in Patients with Rheumatic Diseases

« View all sessions from this meeting